Loading clinical trials...
Loading clinical trials...
A Single-arm, Phase II, Prospective Study of Transcatheter Arterial Chemoembolization, Lenvatinib Combination With Sintilimab Sequential Radiotherapy in Patients With Initial Unresectable Hepatocellular Carcinoma
Conditions
Interventions
TACE, Lenvatinib combination with Sintilimab sequential radiotherapy
Locations
4
China
First Affiliated Hospital of Fujian Medical University
Fuzhou, Fujian, China
Fujian Provincial Hospital
Fuzhou, Fujian, China
Fujian provincial hospital
Fuzhou, Fujian, China
Mengchao Hepatobiliary Hospital of Fujian Medical University
Fuzhou, Fujian, China
Start Date
August 15, 2024
Primary Completion Date
July 1, 2027
Completion Date
July 1, 2028
Last Updated
August 20, 2024
NCT06707233
NCT05911633
NCT06187961
NCT04224636
NCT06397222
NCT05901194
Lead Sponsor
Fujian Provincial Hospital
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions